Skip to main content
TipRanks
Go Ultimate75% OFF

BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis

0 Followers
JP:4594

BrightPath Biotherapeutics Co.Ltd.

(TSE/TYO:4594)

Select Model
Rating:41Neutral
Price Target:JPY 39.00▲(2.63% Upside)
Action:reiterated
Date:10/21/26

Low score primarily due to weak financial performance from sustained losses and cash burn, compounded by bearish technical signals; valuation provides only marginal support given negative earnings metrics.

Positive Factors
Low LeverageVery low leverage reduces refinancing pressure and limits mandatory financing costs while the company remains loss-making. This gives BrightPath greater balance-sheet flexibility to continue research activities and manage funding decisions over the next several quarters.
Negative Factors
Revenue InstabilityThe extreme revenue swing points to weak commercial traction and reliance on uneven milestone or other income rather than a dependable recurring revenue base. Such volatility makes planning difficult and limits confidence that near-term operations can fund development.

BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)

-40%-20%0%20%40%60%JP:4594-37.70%EWJ+16.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.28B
Dividend Yield
―
Average Volume (3M)
1.44M
Price to Earnings (P/E)
-2.9
Beta (1Y)
0.80
Revenue Growth
-94.55%
EPS Growth
-6.51%
Country
Japan
Employees
42
Sector
General
Sector Strength
55
Industry
Biotechnology

BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model

Company Description

BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for...

BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview

Summary

High risk with persistent annual net losses over 1.3 billion, volatile low revenues, and heavy R&D cash burn, though low debt provides limited stability.

Income Statement

15Very Negative

Balance Sheet

35Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue84.00K84.00K1.13M72.00K5.28M15.41M
Gross Profit55.00K55.00K1.10M-341.00K-13.33M-23.03M
EBITDA-1.30B-1.30B-1.15B-1.17B-1.47B-1.45B
Net Income-1.30B-1.30B-1.15B-1.17B-1.49B-1.48B
Balance Sheet
Total Assets2.60B2.60B1.12B1.23B1.70B2.77B
Cash, Cash Equivalents and Short-Term Investments2.16B2.16B810.47M1.06B1.53B2.31B
Total Debt0025.00M112.50M087.50M
Total Liabilities236.41M236.41M195.62M251.27M133.91M239.73M
Stockholders Equity2.37B2.37B924.99M978.99M1.57B2.53B
Cash Flow
Free Cash Flow0-1.37B-1.25B-1.16B-1.21B-1.53B
Operating Cash Flow0-1.37B-1.25B-1.16B-1.20B-1.51B
Investing Cash Flow0-1.93M-1.37M-7.65M-1.76M-17.57M
Financing Cash Flow02.71B1.00B690.96M432.10M569.23M

BrightPath Biotherapeutics Co.Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price38.00

Price Trends

50DMA46.78Negative
100DMA47.93Negative
200DMA55.09Negative

Market Momentum

MACD-2.25Negative
RSI34.47Neutral
STOCH46.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Negative. The current price of 38.00 is below the 20-day moving average (MA) of 39.80, below the 50-day MA of 46.78, and below the 200-day MA of 55.09, indicating a bearish trend. The MACD of -2.25 indicates Negative momentum. The RSI at 34.47 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4594.

BrightPath Biotherapeutics Co.Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4594 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:7096JP:709653NeutralJPY 6.67B58.18――2.55%-43.06%
JP:4880JP:488049NeutralJPY 5.60B56.54―1.77%-9.94%―
JP:4594JP:459441NeutralJPY 5.34B-2.89――-94.55%-6.51%
JP:4593JP:459339UnderperformJPY 30.90B-13.70――-51.55%52.19%
JP:4599JP:459938UnderperformJPY 7.33B-4.01―――4.85%
JP:7776JP:777626UnderperformJPY 6.70B-5.42――-49.43%-3.77%

* General Sector Average

Performance Comparison

-50%-25%0%25%50%JP:4594JP:4593JP:4599JP:4880JP:7096JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4594 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4594BrightPath Biotherapeutics Co.Ltd.38.00-21.00-35.59%
JP:4593Healios KK218.00-233.00-51.66%
JP:4599StemRIM Inc.122.00-154.00-55.80%
JP:4880CellSource Co., Ltd.278.00-217.00-43.84%
JP:7096StemCell Institute640.00-135.00-17.42%
JP:7776CellSeed Inc.162.00-222.00-57.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026